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PROPOSING ADAPTIVE INSULIN DOSAGE  
FOR TYPE 1 DIABETES  
BY FUZZY-BASED CONTROLLER 
SUMMARY 
More than 22 million people worldwide suffer from Type 1 diabetes. In 2030, the 
numbers are expected to get higher. Hence, Diabetus Mellitus becomes a worldwide 
epidemic. In Turkey only, there will be 10 million diabetes patients. Treatment of 
Type 1 diabetes changed drastically after the discovery of insulin and continuous 
subcutaneous insulin infusion (CSII). Moreover, CSII therapy gained widespread 
acceptance with improvements in insulin pump and blood glucose sensor technology. 
This study presents an adaptive closed loop system that proposes insulin dosage to 
regulate the blood glucose level of Type 1 diabetes patients. Developed prototype 
system contains of two Mamdani–type fuzzy logic controllers, database files with 
patient information, response of the system is stored, and insulin on board module 
prevents the user from overlapping injections. One fuzzy controller adjusts the 
amount of insulin by producing a coefficent factor according to the age and body 
mass index of the patient, another one purposes insulin doses comparing the patient’s 
glucose readings. In this prototype, Centroid method, which is the most common 
method used in fuzzy ogic systems, was used for defuzzyfication process. 
Unlike prior studies, our proposed system compares three arbitrary blood glucose 
readings and proposes an insulin dosage to regulate blood glucose level of the 
patient.The system was tested using blood glucose readings of a real type 1 diabetes 
patient. Additionally, a second type-1 diabetus mellitus patient was used to test the 
system stability and adaptive abilities. Moreover, generated insulin dosages were 
compared with the multiple daily injection treatment dosage to prove sytem’s 
reliability. 
Finally, MATLAB programming environment and fuzzy logic toolbox were used to 
design the system. Test results showed that system was adaptable and proposed 
insulin dosages were acceptable for type 1 diabetes mellitus patients. Testswith Type 
1 diabetes patient gave promising results toavoid hypoglicemic events that are the 
biggestdrawback in CSII therapy. 
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TİP-1 DİYABET HASTALARI İÇİN BULANIK MANTIK TABANLI 
KONTROL EDİCİ KULLANARAK UYGUN İNSULİN  
DOZLARININ ÖNERİLMESİ 
ÖZET 
Günümüzün en yaygın hastalıklarından biri diyabettir. Temel olarak Tip1 ve Tip 2 
olmak üzere iki tip diyabet çeşidi vardır. Tüm dünyada 22 milyon kişi Tip 1 diyabet 
hastasıdır. Dünya Sağlık Örgütünün tahminine göre, 2030 yılında bu sayının yaklaşık 
iki katına çıkması beklenmektedir. 2030 yılının sonunda Türkiye’de 10 milyon Tip 1 
ve Tip 2 diyabet hastasının olacağı tahmin edilmektedir. Rakamların ışığında 
diyabeti dünya çapında bir salgın hastalık olarak düşünebiliriz. 
İnsulin ve devamlı derialtı enjeksiyon tedavisinin bulunması ile, hastalığın 
tedavisinde ve geç dönem komplikasyonlarının önlenmesinde önemli gelişmeler kat 
edilmiştir. Buna ek olarak, teknolojik gelişmelere bağlı olarak insulin pompası ve 
kan şekeri sensörlerindeki gelişmeler, özellikle sürekli deri altı enjeksiyon tedavisine 
önemli kolaylıklar ve bu tedavinin pekçok gelişmiş ülkede kabul 
görmesinisağlamıştır. 
Sürekli deri altı enjeksiyon tedavisindeki gelişmeler özellikle çocuk yaştaki Tip 1 
diyabet hastalarının tedavi sürecine hızla uyum sağlamasına olanak vermiştir. Bunun 
yanı sıra her yaş hasta grubunda kan şekeri düzeylerinin kontrolünün yanı sıra, 
hastaların psikolojik olarak da rahatlamalarına yardımcı olduğu yapılan çalışmalar ile 
kanıtlanmıştır. Sürekli deri altı enjeksiyon tedavisinde ki en büyük yenilik, diğer 
tedavi yöntemlerine göre hastaların hayatlarını daha esnek yaşayabilmeleridir. Ancak 
bu tedavinin en büyük dezavantajı iyi ayarlanmayan dozlardan dolayı kan şekeri 
düzeylerindeki değişmeden kaynaklanan hipoglisemik krizlerdir. Bu istenmeyen 
durumun oluşması, hastanın eğitiminin arttırılması ve uygulanacak insulin dozlarının 
kullanılan cihaz tarafından uygun olarak hesaplanması ile giderilebilir. 
Bu çalışmada, Tip 1 diyabet hastaları için insulin dozları öneren ve kan şekeri 
düzeylerindeki değişikliklere uyum sağlayabilen kapalı söngü bir kontrol sistemi 
önerilmektedir.  
Diğer çalışmalardan farklı olarak, önerilen bu sistem, hastaya ait, ard arda alınmış üç 
kan şekeri ölçüm değerini karşılaştırarak, hastaya kan şekeri düzeysini normal 
sınırlarda tutmaya yardımcı olacak insulin dozlarını hesaplar. 
Önerilen bu sistem gönüllü gerçek bir Tip 1 diyabet hastası üzerinde de test 
edilmiştir. Böylelikle hastanın normal tedavisinde kullandığı insulin miktarları ile 
sistem tarafından önerilen insulin miktarları karşılaştırılmıştır. 
Buna ek olarak, sistem farklı kan şekeri profilleri üzerinde denenerek, değişime 
uyum sağladığı ve tutarlı sonuçlar ürettiği gözlemlenmiştir. Böyle bir kontrol 
sisteminin tasarımı için en yaygın yapay zekâ tekniklerinden olan Bulanık Mantık 
tekniği kullanılmıştır. Bu amaçla, tasarlanan kontrol sistemi FIS editörü kullanılarak, 
MATLAB programlama dili ortamında gerçekleştirlmiştir. 
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Tezin birinci bölümünde, diyabet ile ilgili genel bilgilerin yanı sıra, Dünya’da ve 
Türkiye de diyabetin durumu, insan vücudunda şeker düzeylerinin nasıl 
düzenlendiği, şeker hastalığının tanısında kullanılan test yöntemleri, günlük çoklu 
insulin enjeksiyonu ve deri altı sürekli insulin enjeksiyonu tedavileri, insulin 
pompalarının tarihi gelişimi ve tez ile ilgili genel bilgilere yerverilmiştir. Bu bilgilere 
ek olarak günümüzde kullanılan modern insulin pompaları ve özelliklerinin 
bulunduğu bir tabloda bu bölümde yer almaktadır. Ayrıca açık ve kapalı döngü kan 
şekeri kontrol sistemlerinin genel özellikleri ve günümüze kadar yapılmış olan kan 
şekeri düzenlenmesi konusundaki yapay zekâ uygulamaları da tezin bu kısmında özet 
halinde verilmiştir. 
Tezin ikinci kısmında: 
 Bulanık mantığın temelleri,  
 Bulanık mantık kümelerinin çeşitleri ve bunların birbirleri ile birleştirilmesi,  
 Bulanıklaştırma ve berraklaştırma işlemleri,  
 Sugeno ve Mamdani tip bulanık mantık yaklaşımlarının birbirlerine olan 
üstünlükleri  
ayrıntılı bir şekilde anlatılmıştır.  
Bu bilgilere paralel olarakgenetik algoritmalar, yapaysinir ağları gibi diğer yapay 
zekâ uygulamaları ile bulanıkmantık yaklaşımını birleştiren diğer tasarımlara da yer 
verilmiştir. Bu bölümün en son kısmında ise önerilen prototip ile ilgili tasarım 
sürecindeki kısıtlamalara değinilmiştir. 
Tezin üçüncü bölümünde, önerilen sisteminin parçalarının ayrıntılı olarak 
gösterildiği bir şema bulunmaktadır. Bu şemaya göre sistem temel olarak dört 
parçaya ayrılmaktadır. Bunlar  
 Hasta bilgileri ve sözel bulanık mantık kurallarının bulunduğu bir veribankası,  
 Bulanık kontrol ediciler,  
 Daha önce hastaya uygulanmış olan insulin değerlerinin takip edip hipoglisemi 
riskini düşüren insulin takip sistemi ve  
 Tüm veri akılışını kontrol eden ve hastaya enjekte edilecek olan insulin 
miktarının hesaplandığı ana kontrol ünitesidir.  
Daha önceki çalışmalardan farklı olarak, iki adet bulanık mantık kontrol edici sistem 
kullanılmıştır: 
 Bunlardan birincisi hastanın yaş ve vücut kütle indeksine göre gerekli olan bazal 
insulin miktarını hesaplarken,  
 İkinci bulanık mantık kontrol edici hastanın değişen kan şekeri profilini takip 
etmekte ve bu değişim oranına göre hastanın kan şekeri düzeysini normal 
sınırlarda tutmak için kaç ünite insulin enjekte edilmesinin gerektiğini 
hesaplamaktadır. 
Tezin dördüncü bölümünde ise, sistemin güvenilirliğini ve başarımını denemek 
amacı ile yapılan deneylerin sonuçları yer almaktadır. Sistem iki aşamada test 
edilmiştir. Bunların ikisi de gerçek hastalardan alınan verilerle gerçekleştirilmiştir. 
 xxi 
 Test süresinin ilk kısmında çoklu insulin enjeksiyonları tedavisi gören bir 
hastanın tedavisinde kullanılan insulin miktarları ile önerilen sistemin sürekli deri 
altı enjeksiyonu tedavisine göre ürettiği değerler karşılaştırılmıştır. Elde edilen 
ilk veriler, farklı iki tedavi yaklaşımının arasında olması gereken %20’lik doz 
farkının sınırları içinde kalmıştır.  
 Deney aşamasının ikinci kısmında sistem gönüllü gerçek bir hasta üzerinde 
denenmiş, saat başı alının kan şekeri düzeylerine göre hesaplanan dozların 
hastaya enjeksiyonu sağlanmıştır. Toplamda 18 saat süren bu test sonucunda 
hastanın yüksek kan şekeri düzeyleri normal sınrlara inmiş, hipoglisemik tabloya 
rastlanmamıştır.  
Testin tüm aşamalarında okunan değerler ve üretilen insulin dozları, bu bölüm 
içerisinde grafikler ve tablolar ile temsil edilmiştir. 
Tezin en son bölümünde ise, sonuçlar ile ilgili özet verilere ve gelecekte projenin 
nasıl gelişebileceği ile ilgili fikirleredeğinilmiştir. Özellikle devamlı kan şekeri 
ölçümünü sağlamak için geliştirelen sensör teknolojilerinin, bu tarz uzman 
sistemlerin başarılı bir şekilde sonuçlanması için önemli olduğu vurgulanmıştır. Bu 
bölümde bahsedilen diğer bir husus da özellikle görme engelli diyabet hastaları için 
tasarımlarda bazı özelleştirilmelerin yapılması gerektiğidir. 
Test sonuçları, bu tezde önerilen sistemin değişikliklere uyum sağlayabildiğini ve 
önerilen insulin değerlerinin Tip 1 diyabet hastalarının kan şekeri düzeylerinin 
istenilen aralıkta tutulabilmesinde yardımcı olduğunu göstermektedir. Özellikle 
gerçek hasta üzerinde yapılan testlerin sonuçları sürekli derialtı insulin tedavisindeki 
en büyük dezavantaj olan düşük kan şekeri sendromlarını engellemekte ümit 
vaadedicidir. Sonuçlar, kan şekeri kontrolünde kullanılan tedavi yönteminin yanı sıra 
hastanın diyabet ve kan şekeri kontrolü konusunda ki eğitiminin deönemli olduğunu 
göstermiştir. 
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1. INTRODUCTION 
Diabetes Mellitus is a group of metabolic diseases characterized by hyperglycemia, 
resulting from defects in insulin secretion, insulin action, or both [1]. The disease 
prevents glucose in the blood from being absorbed by the cells or used as energy [2]. 
Today, more than 220 million people worldwide suffer from diabetes [3]. According 
to scientists, by 2030 this number will be 366 million [4]. Almost 10% of this 
number are patients with type 1 diabetes [1]. In their everyday life, d are diabetes 
patients dependent on insulin to help their bodies to utilize glucose [2]. The amount 
of needed insulin is not a constant value, since it depends on different factors like 
age, weight, body mass index, and even the insulin injection site [5-8]. If patients are 
unable to supply a given value of insulin, a chain of subsequent diseases can occur 
that may lead to damage, dysfunction and failure of various organs [1, 9].  
This chapter gives an insight to diabetes mellitus and glucose mechanism of the 
human body. Terms as pancreas functions, Type 1 diabetes (T1D), Type2 Diabetes 
(T2D) and insulin are defined, alsothe relation between them, continuous 
subcutaneous insulin infusion therapy, insulin pumps, and basics of fuzzy logic are 
explained in this chapter.  
1.1 Diabetes by Numbers 
Diabetes is an increasing worldwide problem. The number of people with diabetes is 
increasing with population growth, aging, urbanization, increasing prevalence of 
obesity and lack of physical activity [10]. It is estimated that the prevalence of  
diabetes doubles every 15 years [11]. Today 150 million people have diabetes and 80 
% of them are living in low or middle-income countries [1, 12]. By 2030, 
approximately 366 million patients will be diagnosed as diabetic patients. Attaining 
epidemic proportions as the prevalence increase from 2.8 to 4.4 % in all age groups 
(Figure 1.1) [10]. In Turkey, there are 2.9 million diabetes patients. It is estimated 
that by the end of 2030, 6.4 million patient will be diagnosed with diabetes [13, 14]. 
 2 
Figure 1.2  presents the diabetes prevalence according in Turkey's regional areas [13, 
14]. 
 
Figure 1.1 : The number of diabetes patients across the world [14] 
World Health Organization (WHO) implies, diabetes has become an urgent task to 
discover  how to manage diabetes and to reduce the likelihood of its complications 
[15].  A recent research indicates that diabetes in 2010 accounted for 12% of health 
expenditures [16]. Moreover, In Europe, diabetes health care approximately 
consumes about 10% of the total health care budget [17].  
 
Figure 1.2 : Diabetes prevalence according to the Turkey's regional areas [13, 14] 
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1.2 Definition of Diabetes and Glucose-Insulin System 
Diabetes mellitus is often simply referred to as diabetes. “Diabetes” was formed from 
the Greek word for “siphon” by Aretaeus around 100 AD. Ross Molinaro emphasizes 
that word gave rise to its use as the name for a disease involving the discharge of 
excessive amounts of urine [18]. Diabetes is a group of metabolic diseases in which a 
person has high blood sugar either because the pancreas does not produce enough 
insulin, or because cells do not respond to the insulin that is produced. This high 
blood glucose level produces the classical symptoms of polyuria (frequent urination), 
polydipsia (increased thirst) and polyphagia (increased hunger) [12]. 
Glucose is the primary source of energy for the body's cells, and blood lipids (in the 
form of fats and oils) are primarily a compact energy store [12]. Our body has two 
main sources of glucose. One of them is infusion of glucose from meal ingestion, 
oral glucose intake, external nutrition and constant glucose infusion. The other is 
internal glucose production by the liver which is the most prominent organ involved 
in the control of blood glucose concentration (Figure 1.3) [19, 20].  As glucose enters 
the regulatory system from the two main sources, infusion and hepatic production, 
cells within the body use the available glucose.  
 
Figure 1.3 : Scheme of the glucose insulin control system which puts in relation the 
measured plasma concentrations [20] 
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Moreover, there are two types of cells that utilize the available glucose: a cell whose 
glucose consumption is independent of insulin (predominately brain and nervous 
system cells) and a cell whose glucose consumption is facilitated by insulin 
(predominantly muscle and fat cells).  Glucose concentration in our body is not 
constant. 
As can be seen in Figure 1.4, glucose levels are usually lowest in the morning, before 
the first meal of the day and rise after meals for approximately one hour. As the 
levels fluctuate, glucagon and insulin are being secreted by the pancreas to keep 
glucose levels in the plasma in desired interval. However, as the body attempts to 
keep glucose concentration constant, there are some experimentally 
observednaturally occurring stable oscillations in glucose and insulin concentrations. 
Therefore, human body can respond in two ways to regulate the chances in blood 
glucose levels. The first way for regulating low glucose levels and the other way is 
for regulating the high glucose levels.  
 
Figure 1.4 : Typical 24-hour profile of blood glucose concentration [21] 
When blood glucose level drops, the pancreatic α cells secreteglucagon, which 
travels to the liver. In the liver, it facilitates release of glucose from the glycogen 
stores. So blood glucose levels are optimized.  If blood glucose concentration 
becomes higher than it should, a signal is sent to the pancreas, to which pancreatic β 
cells react by secreting the hormone insulin to reduce the glucose concentration in 
the blood stream [22].  
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1.3 Classification of Diabetes 
There are mainly two different types of diabetes mellitus (DM). One of which T1D -
insulin dependent- and the other is type 2 diabetes (T2D) - non-insulin dependent. In 
addition, we can add gestational diabetes and few other sub-types of diabetes [4, 13]. 
T1D comprises approximately 10% and T2D comprises 90% of all people with 
diabetes [1].  
1.3.1 Type 1 diabetes (T1D) 
In T1D, ß cells are destroyed by an autoimmune attack. [23] . There is no way to 
prevent this immune attack. Symptoms develop rapidly. It can be diagnosed when 
the patient is young but it can develop at any age [24]. T1D which is one of the most 
common chronic childhood disease in developed nations [4], is called also ”juvenile 
diabetes” because majority of the diabetes cases are children. It is estimated that 
children younger than 15 years suggest almost 25,000 new case in Europe alone, 
with doubling of incidence in children younger than 5 years [25]. Approximately, 
10% of all the diabetes cases in North America and Europe is T1D [15]. Because of 
the mass ß cell destruction T1D patient becomes dependent on insulin to sustain life. 
They have to inject themselves bolus and basal insulin doses multiple times during 
each day.  
1.3.2 Type 2 diabetes (T2D) 
T2D is more likely to be associated with insulin resistance and relative insulin 
deficiency characterized by impaired insulin secretion and action, or both [26]. In 
simple terms, it means that type 2 diabetes may occur even though there are high 
circulating levels of insulin in the blood (hyperinsulinaemia). The insulin is unable to 
act on its target tissues (insulin resistance), so blood glucose levels rise 
(hyperglycemia). In response to this, more insulin is produced (compensatory 
hyperinsulinaemia) to combat the rise. T2D accounts for about 85-90% of all cases 
of diagnosed diabetes and is see in children and adolescents [23]. T2D is the most 
common form of diabetes. More than %90 of the diabetes patients are recorded as 
T2D patients [4].  
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1.4 Diabetes Diagnosing: History and Evolution 
History of diagnosing diabetes dates back to 100 AD. For 2,000 years diabetes has 
been recognized as a devastating and deadly disease. Aretaeus recognized the general 
symptoms of diabetes but could not efficiently treat it. In the 17th century, Dr. 
Thomas Willis, determined whether his patients had diabetes or not by sampling their 
urine. According to his test if the patient’s urine had a sweet taste he would diagnose 
them with diabetes mellitus- "honeyed" diabetes. Monitoring the blood sugar by this 
method went generally unchanged until the 20th century [18, 27]. In the 1960s urine 
strips were developed. In order to test your blood sugar there were these do-it-
yourself urine kits-blue meant there was no sugar present, and orange meant you 
were positive test result. Urine tests can detect ketones and protein in the urine. Yet 
urine tests alone  was not enough to diagnosing diabetes [2]. After that in 1969 the 
first portable glucose meter was created by Ames Diagnostics [27]. Basic procedure 
has changed very little since then. The first measurement methods used reflectance 
photometry to measure the amount of light, produced by a light emission diode 
reflected from the reagent strip that has a chemical reaction with the drop of patient’s 
blood. By using a photodiode light intensity is measured and then converted to 
electrical signals. After that the readout is displayed. Now most blood glucose 
monitors use an electrochemical methodology to obtain the blood glucose reading 
[1]. 
The diagnostic criteria for diabetes have included the measurement of plasma 
glucose for years. Still there are some disadvantages in using these results as criteria 
for diagnosing the diabetes. In Table 1 you can see the important blood test result 
intervals, which are important diagnosing DM. Table is prepared according to the 
standards of American Diabetes Association (ADA).  
For instance, if a fasting glucose reading (FPG) is used, the patient must fast for at 
least eight hours. According to the Molinaro concentration of a fasting individual’s 
glucose is not the same when measured on different days. Furthermore the obtained 
readings can be change at a different time of the day [18]. Another important issue  is 
the sample stability. The blood taken for glucose testing waits in testing tubes. 
Therefore, glucose in the plasma can continue to metabolize to glucose-6-phosphate. 
Therefore glucose concentrations in the plasma will become lower [18]. An oral  
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Table 1.1 : Important blood test result intervals that help to diagnose DM 
 A1c FPG
1
 OGTT 
2
 
Diabetes  6.5%                     
Pre-Diabetes 
      
      
<126mg/dl 
     mg/dl 
<200 mg/dl 
     mg/dl 
Normal       <100 mg/dl <140 mg/dl 
glucose tolerance test (OGTT) involves blood over a three or five-hour period after a 
patient drinks a specially prepared syrup of glucose and other sugars. During the test 
no other liquids are allowed. In patients with diabetes the blood glucose rises and 
stays elevated after drinking the sweetened liquid. If it is higher than 200mg/dl two 
hours after drinking the syrup that confirms the diagnosis of diabetes [2]. 
The glycated hemoglobin (A1c) test was devised in 1979 in order to create a more 
precise blood sugar measurement. With the A1c, hemoglobin, the oxygen-carrying 
pigment in red blood cells, is used to track glucose changes over a period of four 
months, the life span of the cell. Hemoglobin links with the glucose in blood; the 
more glucose present, the greater amount of hemoglobin linked with glucose [27]. In 
2010 ADA published guidelines for the Diagnosis an Classification of 
DiabetesMellitus. In these guidelines, ADA recommended the use of A1c test to 
diagnose diabetes. There are some advantages to use A1c test. First of all patients do 
not have to fast before the test. In addition, this test gives longer-term results than 
plasma glucose test does. Another advantage is the A1c test does not affected by the 
non-glycemic factors [18]. 
1.5 Treatment Of Diabetes: 
There is no known cure for diabetes. Yet keeping the blood glucose levels within a 
normal range and preventing the development of the development of the long-term 
complications are main goals of diabetes treatment. Tight glycemic control reduces 
not only the risk of long term disturbances like micro vascular disorders(neuropathy, 
retinopathy, nephropathy), stroke, myocardial infarction caused by both type of 
diabetes, but also reduces the cost of the healthcare system [4, 28]. Also, oral 
medication can be applied to T2D patients to block the intestinal absorption of food 
byproducts [2].  
                                                 
1
 FPG : The Fasting Plasma Glucose Test 
2
 OGTT : The Oral Glucose Tolerance Test 
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Hence T1D patients cannot produce insulin; they need daily injections of insulin to 
mimic the insulin production of pancreas for exerting the glucose in blood stream 
[2]. There are two methods for injection. One of them is multi injecting the insulin 
(MDI) under skin using a syringe or insulin pens several times a day. The other way 
is injecting the insulin continuously by using insulin delivery systems like insulin 
pumps called CSII [29]. T2D patients can reduce the high blood glucose level (BGL) 
with tight glycemic control and oral medication [13]. Moreover, Home [30] mentions 
that the real improvement of blood glucose control is possible by better education.  
1.6 Continuous Subcutaneous Insulin Infusion Therapy And Insulin Pumps 
In the late 1970s, continuous subcutaneous insulin infusion (CSII) pump therapy 
opened a new era for treatment of diabetes. Until then, individuals with type 1 
diabetes had to take more than 3 injections each day to keep their blood glucose 
levels within normal ranges [31].  Today, 10% of all type 1 diabetes patients in 
Sweden and Germany use  insulin pumps as part of their treatment [32]. The main 
purpose of the pump therapy is to create a precise, accurate and continuous insulin 
infusion rate to each patient [33]. Therefore individuals that suffer from type 1 
diabetes can have a more flexible life style and avoid complications of diabetes. 
Newer findings on continuous glucose sensors are discussed as the next era of pump 
therapy that continues to focus on the goal of developing an artificial pancreas [31]. 
Control methods used for keeping the blood glucose levels of the type 1 diabetes 
patients constant, therefore, they cannot be applied to CSII therapy directly. 
With the improvements in continuous subcutaneous insulin infusion therapy, the 
management of type 1 diabetes has changed drastically, and there are more 
opportunities to create more advanced control system for insulin pumps [31, 34]. 
1.6.1 Historical evolution of the insulin pump 
Insulin pumps were the first technologies introduced to diabetes care [35].  In the 
early 1960s, Arnold Kadish designed the first closed-loop insulin pump device that 
provide continuous insulin to the patient’s body with the help of automatic blood 
glucose sensing [31]. This artificial pancreas comprised a large pump with an auto 
analyzer, operated to measure blood sugar with an on-off servo-mechanism that 
controlled the pump function when blood sugar was outside normal ranges [36]. 
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Unfortunately, little attention was given to Kadish’s device due to its impracticality 
for daily use, with its size similar to “an army backpack” [31, 37] (Figure 1.5). 
 
Figure 1.5 : Kadish’s first insulin pump [32] 
Greater attention was directed to the first computer controlled closed-loop insulin 
pump, named Biostator which was developed in 1974 (Figure 1.4). This was 
designed to simulate the function of normal pancreatic cells and consisted of a pump 
which controlled continual withdrawal and mixing of blood; a glucose analyzer for 
continuous analysis of blood glucose concentration; a computer programmed with a 
set of algorithms to calculate the amount of insulin or dextrose to be infused based on 
blood glucose level; a computer-operated infusion pump for insulin or dextrose 
delivery; and a printer/plotter for minute-by-minute blood glucose recording . As for 
Kadish’s device, long-term use of the Biostator was restricted by its complexity, 
cumbersome size and intricacy, and so was only used in short-term research studies 
[36]. The pursuit of more practical means of insulin delivery led investigators to use 
continuous intravenous insulin delivery systems [31].  
In the early 1980s, the first custom designed microprocessor-controlled insulin pump 
was introduced, which was designed by the Mill Hill and Guy’s Hospital team [19]. 
The product was licensed for commercial use in 1983 and was named the Nordisk 
infuser. Early commercial insulin pumps suffered from performance and reliability 
problems. They were large, being the size of a house brick and weighing up to 400 g; 
their batteries needed to be recharged too frequently; had limited safety alarms; 
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lacked control of safe insulin delivery; offered very little flexibility in the rate of 
basal insulin delivery; had infusion sets with metal needles; and some required the 
use of a screwdriver for dosage adjustment [32]. As a result, clinical complications of 
diabetes such as hyperglycemia, diabetic ketoacidosis and infection at the injection 
site were common with early pumps, causing limited acceptance and use of this 
technology throughout the 1980s by both healthcare professionals and patients.  
 
Figure 1.6 : Biostator [31] 
The 1990s represented a new era in the development of insulin infusion pumps, 
where the technical problems of the early devices such as pump malfunction [31] 
(either not working or releasing extra insulin; insulin leakage) and tubing occlusion 
were largely resolved. Production began of more functional pumps with safety 
measures that gave alarms and alerts for problems such as infusion set occlusion, as 
well as a ‘low’ battery or low insulin reservoir .  
Today, patients/clinicians have a variety of devices to select from. It has been 
possible to manufacture pager-sized pumps with enhanced safety measures and long-
life batteries, which can be provided with plastic catheter infusion sets to reduce the 
problem of site infection. In addition, pumps are now manufactured in a variety of 
colors and have large screens where the displayed information is easy to read. Recent 
insulin pumps allow patients to program several different basal rates to be used in 
one day to accommodate diurnal changes in insulin needs [19] . Based on the user 
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carbohydrates inputs, most modern insulin pumps can calculate bolus doses as well 
as doses needed to adjust high blood glucose values when needed. Some recent 
pumps, termed ‘smart pumps’ (Table 2), have built-in dosage calculators to perform 
an automatic estimation of insulin remaining active from a previous bolus, and can 
estimate the amount of insulin that should be administered based on several factors, 
such as blood glucose concentration and anticipated amount of ingested food. 
Currently, different manufacturers compete to produce insulin pumps with unique 
features and designs that offer users comfort, flexibility, and ease of use. The insulin 
pump market today is growing by approximately 50% per year, indicating that the 
technology fills a genuine need, and has proven capability (36). 
1.6.2 Modern pumps and their properties 
Since the discovery of insulin, a number of innovations in insulin delivery devices 
have been made [6]. One of these technologies is insulin pump. In US 20-25% of the 
T1D patients, in Sweden and Germany 10% of the T1D patients are using insulin 
pump. Patients’ preference for and acceptance of insulin pumps over conventional 
injection therapy has increased over the years [38]. This is likely to be due to the 
development of newer pumps with reduced size and efficient performance.  
 
Figure 1.7 : Modern insulin pump [31] 
A modern insulin pump (Figure 1.7) is a pager size device, which consists of a 
reservoir, a pumping mechanism, and an infusion rate controller. A fine catheter 
delivers the insulin from the pump at a slow basal rate to the subcutaneous tissue, 
with patient-activated insulin bolus at meal times [1]. Pumps give opportunity to 
apply rapid insulin analogs to mimic the function of a healthy pancreas [7].  The 
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technological capabilities of pumps have also advanced. Programmable pumps have 
allowed for titration of basal rates and varying bolus doses with a wide array of 
delivery options (Table 2). Programmable pumps have been shown to lead to 
improved glycemic control and fewer episodes of overnight hypoglycemia versus 
nonprogrammable pumps [39]. One of the features of pumps that are particularly 
important in treating adolescents with T1D is the bolus history function, which 
allows clinicians and parents to assess whether patients are missing bolus doses of 
insulin. 
 
Figure 1.8: Insulin profile generated by insulin pump [1] 
Insulin pump is unique in that is the only system that permits the user to vary and 
adjust basal insulin levels [40]. As can be seen on Figure 1.4, pumps can give basal 
insulin as defined by the user and before meals can infuse bolus doses according to 
the patients’ needs. In open loop systems the insulin rate is calculated by the input 
entered by the user like the quantity of carbohydrate. On the contrary, in closed loop 
systems insulin calculated according to the information taken from glucose sensor. A 
closed-loop device (Figure 1.9) that maintains normal glycemic levels over extended 
periods of time could dramatically improve the quality of metabolic control of 
insulin-dependent diabetic patients [1]. 
There are six leader manufacturers supplying insulin pumps worldwide: Medtronic 
Mini- Med, Roche’s Disetronic Medical Systems, Animas (Johnson & Johnson), 
Deltec (Smiths Group), Sooil and Insulet Cooperation Ltd. Medtronic MiniMed is a 
US-based company, and is the market leader for insulin pumps (Paradigm pumps) in 
the US, having approximately 85% of market share [49]. Roche’s Disetronic is the 
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market leader outside the US. Until 2000, the main pump manufacturers dominating 
the pump market were Medtronic MiniMed and Disetronic [49]. Animas, launched 
its first generation insulin pumps in 2001 (Paradigm pumps) in the US, having 
approximately 85% of market share [49]. Roche’s Disetronic is the market leader 
outside the US. Until 2000, the main pump manufacturers dominating the pump 
market were Medtronic MiniMed and Disetronic [49]. Animas, launched its first 
generation insulin pumps in 2001. 
Table 1.2 : Features of The Latest Insulin Pumps [41-48]   
Company Medtronic Roche Animas Insulet Deltec Sooil 
Model 
Paradigm 
522/722 
Accu-Check 
Spirit 
IR-2020 Omnipod Cozmo 1800 
Dana 
Diacare 
IISG 
Insulin 
Resarvoir 
Capacity 
176/ 300 u 315 u 200 u 200 u 300 u 300 u 
Minimum 
Basal Rate 
Increament 
0.05 u 0.1 u 0.0025 u 0.05 u 0.05 u 0.1 u 
Minimum 
Bolus Rate 
Increament 
0.1u , 0.5 u 0.1-2.0 u 0.05-5.0u 0.05 -1.0 u 0.05 -1.0 u 0.1-8.7 u 
Delivery 
Varies, 
every 10 
min. 
Every 3 min. Every 3 min. N.A Every 4 min. 
Every 3 or 
15 min. 
Safety 
Feature 
Alarm,  
Key-lock 
function 
Alarm,  
Key-lock 
function 
Alarm 
Alarm,  
Key-lock 
function 
Alarm,  
Key-lock 
function 
Alarm,  
Key-lock 
function 
Price     
[Euros 
(Dollars]) 
€3518 
($5277) 
€3038 
($4558) 
€3326 
($4990) 
N.A 
€3518 
($5277) 
N.A 
u= Units of insulin 
 
Figure 1.9 : Closed loop blood glucose control [1] 
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Sooil and Nipro manufacture devices for continuous subcutaneous insulin delivery, 
Dana Diabecare Pumps and Amigo Pumps, respectively. The latest manufacturer of 
insulin pumps is Insulet which produces OmniPod disposable insulin pumps, which 
received FDA approval in January 2005 [49]. In Turkey only Medtronic Mini- Med 
devices are being sold. If you are a diabetes patient, with your endocrinologist 
confirmation, you can buy an insulin pump with the health insurance of the Ministry 
of Health.  
1.7 Literature Survey 
In 1993 the Diabetes Control and Complications Trial published compelling 
evidence that "intensive therapy with the goal of maintaining blood glucose 
concentrations close to the normal range, effectively delays the onset and slows the 
progression of diabetic retinopathy, nephropathy, and neuropathy in patients with 
insulin-dependent diabetes mellitus". As many of the studies demonstrating the 
effectiveness of pump therapy [6, 7, 9, 32, 38, 39, 49-58] were completed, insulin 
analogues and technological advances changed the way in which CSII pump therapy 
evolved and many studies were done.  
Grant [53] claims that “we sought to explore the use of insulin pumps and the 
application of fuzzy logic technology to act as an ‘artificial pancreas’ in diabetic 
patients”. According to him fuzzy logic controllers have shown relatively successful 
results if we compare with the well-known conventional controllers such as 
proportional-integral-derivative (PID). Also in his research he gives a comparison 
between fuzzy PI controller and classical control methods [59]. He claims that a 
fuzzy PI controller is more effective than other classical control methods. Moreover, 
he claims fuzzy logic systems’ failures are rare and they remain as good as their 
programmed goals. Regarding this idea, plenty of studies weredone to create a fuzzy 
logic control algorithm for insulin pumps. Additionally, Li and Hu [60] proposed two 
different control methods for BGL control; one of them is  a PID system and the 
other one is a fuzzy-PID system. According to their results, the fuzzy-PID controller 
is very effective than the PID controller, in blood glucose regulation terms. They 
claim that fuzzy-PID controller can control the glucose concentration better, and the 
regulation of profile approaches that the normal person. Delgado [61] studied a 
Mamdani type fuzzy logic system that estimated the insulin rate according to the rate 
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according to the rate of change in glucose. Moreover, they used inner and outer loop 
controllers to regulate BGL properly. One of them supervised the BGL at the scale of 
days and the other one of controls the BGL during the course of the day.  
In another study, Yasini [62] proposed an active insulin infusion control algorithm 
using Mamdani-type fuzzy scheme. He used two inputs, which are glucose 
concentration and glucose deviation to generate an output. Also in the system 
thereare 21 rules defined in the proposed controller, that provide the possibility of 
more accurate control of blood glucose level in the patient in spite of uncertainty in 
model and measurement noise. He argued that fuzzy logic framework has the 
potential to synthesize expert knowledge to treat diseases and his method has 
preference over other conventional techniques in blood glucose control. As Scheiner 
indicated in his study [40], the age of the patient plays critical role for requirement of 
the insulin amount; moreover, he implied that there are no significant differences 
between males and females basal insulin requirements. In addition to that fact, the 
BMI and the weight of the patient were also important to decide the amount of 
insulin. 
Also, using MATLAB, Jayaraj and Cherian by software tried to create a fuzzy 
control algorithm using BMI and blood glucose readings as inputs [63]. By taking 
the body mass index (BMI) as an input they try to create a system, which takes into 
consideration that the need of the insulin varies from patient to patient. Their 
research shows that using a fuzzy type of reasoning enables their system to predict 
what a human would do. Moreover, he claimed that fuzzy logic is a versatile logic 
that is appropriate for usage solving the complex control problem of controlling BGL 
as it mimics human decision making. Although simulation results were acceptable, 
their study targeted one kind of patient and could not adapt itself to different 
patients’ needs of insulin. Also Dazzi [64] tried to improve the blood glucose control 
by combining fuzzy logic principles and neural network technique.  
These hybrid models’ calculations are accurate; however their structures are more 
complex. Additionally, Zarkogianni [58] developed a non-linear model predictive 
controller which uses a neural hybrid model. This model makes estimations of proper 
insulin infusion rates.  Yasini [62] argued that, “complex models though are accurate 
for regimen evaluation but are generally unsuited for real-time control due to they 
need several time points of input to produce the insulin infusion profile”. Therefore 
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using less complex systems reduces the response time and enables us to calculate 
expected insulin faster. 
Some researchers tried to combine other soft computing methods with fuzzy logic to 
close the loop and program more reliable systems. For example, in his El-Jabali [65] 
tried to create a neural network model which mimics the pancreas secretion of insulin 
in the body, using database on progression of the T1D for a group of diabetics 
patients.  They tried to develop dynamic simulation of T1D and an infuser, which 
releases insulin to keep the BGL in optimum levels. They claimed that “The model 
presented in this study can reliably estimate the next glucose level, as well as the 
appropriate amount of insulin to be delivered, in order to normalize the homeostasis 
with type 1 diabetes” [65] . In another study, Osgouie [66] to make the treatment 
more personal used fuzzy logic system and optimization of it, he used genetic 
algorithm. He claimed that the system is very convenient for real time 
implementations.  
To close the loop is essential to generate a proper control system for closed loop CSII 
therapy. Yet some researchers defined the properties of the ones who is capable to 
use insulin pumps and when the insulin pump therapy is needed. For instance;  
Didangelos [7]  described the insulin pump therapy in adults and gave information on  
benefits and risks of the CSII pump therapy. Moreover, he stated the contradictions 
of CSII therapy. Also, Lassmann [38] implied that “the efficacy of pumps using 
rapid-acting insulin analogues, considered the ‘gold standard’ of insulin treatment. 
Nevertheless, given its theoretical and practical advantages, some patients will derive 
more benefit from pump treatment.” Therefore, the well-working control system is 
not the only factor in pump therapy. In addition, specific education on pump 
treatment is crucial.  
1.8 Summary of Thesis Contributions 
The aim of this study was to evaluate a Mamdani type fuzzy logic model for insulin 
pumps with a closed loop control system that can calculate the proper amount of 
insulin for every type 1 diabetes patient. Research on long-term diabetic 
complications concludes that lowering the average blood glucose has a beneficial 
effect and this will be the performance goal of the implemented control algorithm. 
To achieve this goal, unlike the previous studies, the insulin dose calculated by 
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comparing three arbitrary blood glucose readings according to the fuzzy linguistic 
rules. Main difference from these studies is that our system uses three inputs to 
compare and reflect the general profile of blood glucose levels. In addition, our 
system adapts itself according to the changing in different BGL profiles. To propose 
more personalized insulin dosages, our system uses another Mamdani fuzzy system 
that determines the daily insulin by comparing patients’ BMI and age. As a result, 
systems calculate a specific coefficient factor for every patient. This feature enables 
the main program to calculate the average basal rate and total daily insulin according 
to the data for each patient.  
Moreover, unlike the previous studies, that defined fuzzy sets, we used Gaussian 
functions to describe the fuzzy sets. Main reason for that is, our values were not 
strictly compact. Additionally, Gaussian fuzzy membership functions represent 
vague terms properly. For transformation of the fuzzy information into crisp 
information, center of gravity method is being used. Reducing average blood glucose 
concentrations comes with the risk of increasing hypoglycemic incidents, so 
performance of the control algorithm will also be closely connected to its ability to 
avoid hypoglycemia. Proposed system has another important sub-system, which is 
called insulin on board module to avoid hypoglycemic events. This part keeps the 
track of the injected insulin to prevent overlapping of the injected insulin. By this 
detection, the probability of occurrence of hypoglycemic events is getting lower. 
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2.  ARTIFICIAL INTELLIGENCE AND INSULIN PUMPS 
This chapter provides a brief overview of the disciplines of Artificial Intelligence 
(AI), subfields of AI and studies about intelligent pumps that use this kind of soft 
computing methods. It introduces the topics covered under the heads of intelligent 
systems. It also gives information about the development in AI and addresses new 
methods use for solve complex problems. At the end of the chapter, problems about 
CSII therapy and solutions defined. In addition, limitations of our proposed system 
are explained.  
2.1 Introduction Artificial Intelligent 
At the beginning of the Stone Age, when people started taking shelters in caves, they 
tried to immortalize themselves by painting their images on rocks. With the gradual 
progress in civilization, they felt interested to see themselves in different forms. 
Therefore, they started to recreate models of human beings with materials. They 
managed to create models that looked like humans but man was not happy with the 
models that only “looked like” him. He had a strong desire to make the model 
‘intelligent’, so that it could “act and think” as he did. During the period of 1981-
1990 the Japanese Government started to produce the 5th generation computing 
machines that could process intelligence. The computers of the current (5th) 
generation can process natural languages, play games, recognize images of objects 
and prove mathematical theorems, all of which lie in the domain of AI [67].  
Before explaining AI, it is crucial to define intelligent. In psychology, intelligence is 
defined as the capability of finding efficient solutions to any new problem. 
According to one other view, intelligence is the ability of learning, understanding 
and thinking. These abilities are biologically concentrated in the brain. However, 
physical size of any brain is usually not directly proportional with intelligence. As 
known, that some living beings (such as worms) who do not have a brain show some 
signs of intelligence [68]. According to these definitions, AI is the intelligence of 
machines and robots and the branch of computer science that aims to create it. AI 
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textbooks define the field as "the study and design of intelligent agents" where an 
intelligent agent is a system that perceives its environment and takes actions to  
maximize its chances of success [69]. Artificial intelligence researchers showed that 
machines couldperform some tasksthat require intelligence through proper 
programming. According to that, if a process needs completely well defined and 
understood mechanism, then machines (computer programs) can give effective 
results. At that point, these programs can be defined as having some “intelligence” 
[69].  
2.2 Fuzzy Logic 
As a human being we experience the world within which we live and use our ability 
to reason to create an order from the mass of information we receive. According to 
the Sivinandam [70],  there is an inherent impreciseness present in our natural 
language when we describe phenomena that do not have sharply defined boundaries. 
Statements as “Ayşe is tall” and “Ayşe is young” are simple examples.  Concepts 
that we use to define the world can be called fuzzy concepts. Moreover, Oxford 
English Dictionary describes the word “fuzzy” as “blurred, imprecisely defined, and 
vague”.  According to Zadeh, fuzzy logic (FL) is concerned  with  the  formal  
principles  of  approximate  reasoning,  with  precise reasoning  viewed as a limiting 
case [71].  
Fuzzy Logic is a tool for dealing with uncertainty. Fuzzy sets are mathematical 
objects modeling this impreciseness. Our main concern is representing, 
manipulating, and drawing inferences from such imprecise statements. Fuzzy set 
theory provides mathematical tools for carrying out approximate reasoning processes 
when available information is uncertain, incomplete, imprecise, or vague [72]. By 
using the concept of degrees of membership to give a mathematical definition of 
fuzzy sets, we increase the number of circumstances encountered in human reasoning 
that can be subjected to scientific investigation.  
Humans do many things that can be classified as control, such as, riding a bicycle. 
We do not have the benefit of precise measurements, or a system of differential 
equations, to tell us how to control our motion, but humans can nevertheless become 
very skillful at carrying out very complicated tasks. One explanation is that we learn 
through experience, common sense, and coaching to follow an untold number of 
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basic if-then rules. The use of basic rules of this form is the basic idea behind fuzzy 
control. Linguistic variables such as fast, slow, large, medium, and small are 
translated into fuzzy sets; mathematical versions of if-then rules are formed by 
combining these fuzzy sets.Therefore, fuzzy logic sets were used in this project to 
provide a technique to deal with uncertainty and imprecision of the blood glucose 
levels of patients.  
«Fuzzy systems are an alternative to traditional notions ofa set membership and logic 
that has its origins in ancient Greek philosophy. The precision of mathematics owes 
its success in large part to the efforts of Aristotle and the philosophers who preceded 
him. It is easy to express rules in words, so fuzzy theory provides a mechanism for 
representing linguistic constructs. Yet, linguistic rules need to be represented in 
mathematical way.The mathematical modeling of fuzzy concepts was first presented 
by Professor Lotfi Zadeh in 1965 to mathematically describe classes of objects that 
do not have precisely defined criteria of membership. His intentionwas to represent 
states in natural language in levels. This conclusion is reached by a computer 
program comparing the statements with defined rules [53, 73].  A fuzzy logic system 
(FLS) can be defined as the nonlinear mapping of an input data set to a scalar output 
data. A FLS consists of four main parts: fuzzifier, rules, inference engine, and 
defuzzfier. These components and the general architecture of a FLS are shown in 
Figure 2.1. 
 
Figure 2.1 : General structure of a fuzzy logic system [74] 
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In generally, the fuzzy logic (Figure 2.4)provides an inference structure that enables 
appropriate human reasoning capabilities using vague or grey concepts [70]. These 
vague concepts like low or high can be translated into mathematical expressions, 
which are called membership functions. This translation process is called 
fuzzyfication. Moreover “if-then” statements can be formulated to describe the 
interaction between all membership functions and output. With these rules, fuzzy 
control system can calculate proper output according to given inputs. Output must be 
translated to see the results as numerical values.  This transformation process is 
called defuzzification. There is more than one way to defuzzify the output. The most 
common way is the “center of gravity” method also called center of area method. 
2.2.1 Fuzzy sets and crisp sets 
The very basic notion of fuzzy systems is a fuzzy (sub)set. In classical mathematics 
we are familiar with what we call crisp sets. The crisp sets are defined by means of 
finite or crisp. On the contrary, fuzzy sets are defined by vague and 
ambiguousproperties, hence the boundaries are specified ambiguously.  Fuzzy set 
theory is an efficient theory in dealing with the concepts of ambiguity [70].   
Consider a classical set where X represents the universal set. The individual elements 
in the universe X will be denoted as x. The features of the elements in X can be 
discrete, countable integers, or continuous valued quantities, such as, the clock 
speeds of computers’ CPU or the operating temperature of an air conditioner.  
Choosing a universe that is discrete and finite or one that it continuous and infinite is 
a modeling choice, the choice does not alter the characterization of sets defined on 
the universe. If the universe possesses continuous elements, then the corresponding 
set defined on the universe will also be continuous The total number of elements in a 
universe X is called its cardinal number and is denoted by ηx. Discrete universe is 
composed of countable finite collection of elements and has a finite cardinal number 
and the continuous universe consists of uncountable or infinite collection of elements 
and thus has an infinite cardinal number. The collection of all the elements in the 
universe is called the whole set [70, 72]. The null set, which has no elements is 
analogous to an impossible event, a whole set is analogous to a certain event. Power 
set constitutes all possible sets of X and is denoted by P(X). In the classical set, this 
characteristic function assigns a value of either 0 or 1 to each individual in the 
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universal set. On the other hand a fuzzy set contains elements that have varying 
degrees of membership in the set. Fuzzy set is mapped in to a real numbered value in 
the interval of 0 to 1. 
2.2.2 Operations on fuzzy sets 
A membership function (MF) is a curve that defines how each point in the input 
space is mapped to a membership value between 0 and 1.  Nguyen [72], claimed that, 
«the shape of a membership function depends on the notion the set is intended to 
describe and on the particular application involved». The most frequently used 
membership functions are triangular, trapezoidal (Figure 2.2), Gaussian, and 
sigmoidal Z- and S-functions.  
 
Figure 2.2 : Triangular and trapezoidal membership functions 
The triangular function A with endpoints (a, 0) and (b, 0), and high point (c, α) is 
defined as [72] in Equation 2.1: 
 A(x)=
{
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 (2.1) 
The trapezoidal function B with endpoints (a, 0) and (b, 0), and high points (c, α) and 
(d,α) is defined as [72] in Equation 2.2: 
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Several fuzzy sets are often depicted in the same plot, as Figure 2.3: 
 
Figure 2.3 : Combined fuzzy sets 
The Gaussian functions, the familiar bell shaped curve, are of the form  
         (
           
  
) (2.3) 
These are related to the well-known normal or Gaussian distributions in probability 
and have useful mathematical properties (Figure 2.4). 
 
Figure 2.4 : An example Gaussian curve 
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The parameters c and σ determine the center and the shape of the curve, respectively. 
The values c = 0 and σ = 1 define the standard Gaussian membership function 
        
  
 , centered at c = 0, and with area under the curve equal to   √  . 
This is the Gaussian curve depicted on the above (Figure 2.4). 
In addition, the S- and Z-functions are sigmoidal functions of the form can be seen in 
Figure 2.5: 
 
       (1-tanh x) (1+tanh x) 
Figure 2.5 : Z (left) and S(right) membership functions 
The values of σ determine either increasing or decreasing functions, while the 
parameter m shifts the function right or left. These same shapes can be achieved with 
hyperbolic tangent functions (Equation 2.4) [72].  
  
 
          (
 
     
) (2.4) 
All of these functions can be useful for different applications. According to the 
application we want to define, we use different types of the membership functions. 
To sum everything up, fuzzy sets describe vague concepts (e.g., fast runner, hot 
weather, and weekend days). In addition, a fuzzy set admits the possibility of partial 
membership in it. (e.g. the weather is rather hot). Hence, a membership function 
associated with a given fuzzy set maps an input value to its appropriate membership 
value [70, 75]. 
2.2.3 Combining fuzzy sets 
Fuzzy logical reasoning is a superset of standard Boolean logic. In other words, if  
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you keep the fuzzy values at their extremes of 1 (completely true), and 0 (completely 
false), standard logical operations will hold (Figure 2.6). 
 
Figure 2.6 : Standard classical logic truth tables [75] 
In fuzzy logic the truth of any statement is a matter of degree. Therefore,“min” 
operation resolve the statement A AND B where A and B are limited to the range 
(0,1). Their representation of  “min” operation is min(A,B) [70, 75]. Besides, we can 
replace OR operation with the max function, so that A OR B becomes equivalent to 
max(A,B). Finally, the operation NOT A becomes equivalent to the operation 1− A. 
Figure 2.7 represents  how the previous truth table is completely unchanged by this 
substitution [75].  
 
Figure 2.7 : Standard truth tables with MAX, MIN and NOT operator [75] 
Figure 2.8 uses a graph to show the same information. In this figure, the truth table is 
converted to a plot of two fuzzy sets applied together to create one fuzzy set. The 
upper part of the figure displays plots corresponding to the preceding two-valued 
truth tables, while the lower part of the figure displays how the operations work over 
a continuously varying range of truth values A and B according to the fuzzy 
operations you have defined. Given these three functions, you can resolve any 
construction using fuzzy sets and the fuzzy logical operation AND, OR, and NOT 
[75]. 
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Figure 2.8 : Comparison between classical logic operations and fuzzy logic 
operations [75] 
The classical operators for these functions are defined in fuzzy reasoning as AND = 
min, OR = max, and NOT = additive complement. Most fuzzy logic applications 
make use of these operations.  In general, fuzzy logic uses the classical operator for 
the fuzzy complement as in Figure 2.8 [70, 72]. The intersection of two fuzzy sets A 
and B is specified in general by a binary mapping T, which aggregates two 
membership functions as follows [70]: 
μA∩B(x) = T(μA(x), μB(x)) 
For example, the binary operator T may represent the multiplication of μA (x)and μB 
(x) . These fuzzy intersection operators, which are usually referred to as T-norm 
(Triangular norm) operators, meet the following basic requirements [70, 75]: 
A T-norm operator is a binary mapping T(.,.) satisfying 
boundary: T(0, 0) = 0, T(a, 1) = T(1, a) = a 
monotonicity: T(a, b) <= T(c, d) if a <= c and b <= d 
commutativity: T(a, b) = T(b, a) 
associativity: T(a, T(b, c)) = T(T(a, b), c) 
Like fuzzy intersection, the fuzzy union operator is specified in general by a binary 
mapping S [70]: 
μA∪B(x) = S(μA(x), μB(x)) 
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For example, the binary operator S can represent the addition of μA (x)and μB (x) . 
These fuzzy union operators, which are often referred to as T-conorm (or S-norm) 
operators, must satisfy the following basic requirement [70, 75]: 
A T-conorm (or S-norm) operator is a binary mapping S(.,.) satisfying 
boundary: S(1, 1) = 1, S(a, 0) = S(0, a) = a 
monotonicity: S(a, b) <= S(c, d) if a <= c and b <= d 
commutativity: S(a, b) = S(b, a) 
associativity: S(a, S(b, c)) = S(S(a, b), c) 
2.2.4 Combining fuzzy rules 
We experience the world and use our ability to reason to create order in the mass of 
information. We use verbs to communicate and disclose a new skill to another 
human. For better artificialintelligence, we need some rules that help us guide the 
computer about our experiences and make it to decide as a human being does. Then, 
fuzzy sets and fuzzy operators are the subjects and verbs of fuzzy logic [70]. These 
if-then rule statements are used to formulate the conditional statements that comprise 
fuzzy logic [70, 72].  
«A single fuzzy if-then rule assumes the form if x is A then y is B where A and B are 
linguistic values defined by fuzzy sets on the ranges (universes of discourse) X and 
Y, respectively» [72]. The if-part of the rule “x is A” is called the antecedent or 
premise, while the then-part of the rule “y is B” is called the consequent or 
conclusion. An example of such a rule might be “If service is good then tip is 
average”. 
«The concept good is represented as a number between 0 and 1, and so the 
antecedent is an interpretation that returns a single number between 0 and 1. 
Conversely, average is represented as a fuzzy set, and so the consequent is an 
assignment that assigns the entire fuzzy set B to the output variable y» [72]. In the if-
then rule, the word is gets used in two entirely different ways depending on whether 
it appears in the antecedent or the consequent. In MATLAB terms [75], this usage is 
the distinction between a relational test using “==” and a variable assignment using 
the “=” symbol. We can simplify the representation of the rule by writing like below: 
If service == good then tip = average 
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In general, the input to an if-then rule is the current value for the input variable (in 
this case, service) and the output is an entire fuzzy set (in this case, average). This set 
will later be defuzzified (Figure 2.1 )which is described in next section. «Interpreting 
an if-then rule involves distinct parts: first evaluating the antecedent (which involves 
fuzzifying the input and applying any necessary fuzzy operators) and second applying 
that result to the consequent (known as implication) » [75]. 
In the case of two-valued or binary logic, if-then rules do not present much difficulty. 
If the premise is true, then the conclusion is true. If the antecedent is true to some 
degree of membership, then the consequent is also true to that same degree [75]. The 
antecedent of a rule can have multiple parts.”if sky is gray and wind is strong and 
barometer is falling, then ... “ in which case all parts of the antecedent are calculated 
simultaneously and resolved to a single number using the logical operators described 
in the preceding section. The consequent of a rule can also have multiple parts. 
if temperature is cold then hot water valve is open and cold water valve is shut 
which case all consequents are affected equally by the result of the antecedent. The 
consequent specifies a fuzzy set be assigned to the output. The implication function 
then modifies that fuzzy set to the degree specified by the antecedent.The most 
common ways to modify the output fuzzy set are truncation usingthe min function 
(Figure 2.12) or scaling using the prod function (Figure 2.12) [70, 72, 75].  
2.2.5 Defuzzification 
The input for the defuzzification process is a fuzzy set (the aggregate output fuzzy 
set) and the output is a single number. As much as fuzziness helps the rule evaluation 
during the intermediate steps, the final desired output for each variable is generally a 
single number. However, «the aggregate of a fuzzy set encompasses a range of 
output values, and so must be defuzzified in order to resolve a single output value 
from the set. Perhaps the most popular defuzzification method is the centroid 
calculation, which returns the center of area under the curve» [75, 76]. Figure 2.13 
shows the actual full-size fuzzy inference diagram [70]. For instance, from this 
diagram with these particular inputs, you can easily see that the implication method 
is truncation with the min function [75]. The max function is being used for the fuzzy 
OR operation. Rule 3 (the bottom-most row in the diagram shown previously) is 
having the strongest influence on the output. 
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Figure 2.9 : Fuzzy min and max operations [75]  
2.2.6 Sugeno and Mamdani systems 
There are two types of Fuzzy inference system (FIS). One of them is Sugeno system 
and the other is Mamdani system. These two types of inference systems vary 
somewhat in the way outputs are determined. In Table 2.1, you can see the 
advantages of each inference system [75] . Although Sugeno type inference system 
has many advantages, Mamdani type method is widely accepted for capturing expert 
knowledge. However,  Mamdani-type FIS entails a substantial computational burden. 
Sugeno method is computationally efficient and works well with optimization and 
adaptive techniques, which makes it very attractive in control problems, particularly 
for dynamic nonlinear systems. These adaptive techniques can be used to customize 
the membership functions so that fuzzy system best models the data. The most 
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Figure 2.10 : Fuzzy inference system and defuzzification (centroid) process [75] 
fundamental difference between Mamdani-type FIS and Sugeno-type FIS is the way 
the crisp output is generated from the fuzzy inputs. While Mamdani-type FIS uses 
the technique of defuzzification of a fuzzy output, Sugeno-type FIS uses weighted 
average to compute the crisp output. The expressive power and interpretability of 
Mamdani output is lost in the Sugeno FIS since the consequents of the rules are not 
fuzzy. However, Sugeno has better processing time since the weighted average 
replace the time consuming defuzzification process. Due to the interpretable and 
intuitive nature of the rule base, Mamdani-type FIS is widely used in particular for 
decision support application. Other differences are that Mamdani FIS has output 
membership functions whereas Sugeno FIS has no output membership functions [75, 
76].  
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Table 2.1 : Advantages of Sugeno type and Mamdani type inference systems 
Advantages of Sugeno Method Advantages of Mamdani Method 
•  It is computationally efficient. 
•  It works well with linear techniques 
(e.g., PID control). 
•  It works well with optimization and 
adaptive techniques. 
•  It has guaranteed continuity of the 
output surface. 
•  It is well suited to mathematical 
analysis. 
•  It is intuitive. 
•  It has widespread acceptance. 
•  It is well suited to human input. 
2.3 Fuzzy Logic and Insulin Pumps 
In this part more information is given about literatureon intelligent insulin pump. 
Search for closing the control loop of insulin-glucose control system, led researches 
to AI and soft computing. Previous studies using classical control methods were 
effective but not enough to close the control loop. Grand [53] claimed that fuzzy 
logic is an essential guide that help us to discover artificial pancreas. Also he implied 
that this complex control problem could be solved by the help of fuzzy logic.  
In his study Li  [60] combined a PID controller and fuzzy logic (Figure 2.14). He 
compared the result with classic PID controller and implied that the fuzzy logic 
makes the results better. He claimed that his fuzzy-PID controller has a better impact 
on controlling the BGL. Additionally, Delgado [61] created a more complex system 
than previous studies about fuzzy controlled insulin pumps. His control diagram can 
be seen in Figure 2.15. Control system has inner and outer control loops to regulate 
BGL. Fuzzy system’s rules are created by glucose deviation amounts and glucose 
increment amounts. Purposed system is being tested by different simulation and 
cases. His results showed that fuzzy logic also effective method for solving a 
complex puzzle like insulin glucose regulation system. Fuzzy based systems are 
generally similar to each other. Differences are in membership functions, defined 
linguistic rules and input and output characteristics. After researchers proved that 
fuzzy logic system is efficient on controlling insulin infusion and BGL control, some 
of them took one step ahead and tried to combine different soft computing methods. 
For instance;  Dazzi  [64] combined ANN and fuzzy logic and created a neuro-fuzzy 
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system. Osgouie [77] created a control system  (Figure 2.16 ) using genetic 
algorithms  to optimize the solutions generated by fuzzy logic inference system. 
 
Figure 2.11 : Fuzzy PID controller designed by Li [60] 
 
Figure 2.12 : Control diagram of fuzzy based blood glucose regulation controller 
designed by Delgado [61] 
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Figure 2.13 : Osgouiei’s BGL regulation control system [77] 
2.4 Problem Formulation 
Patients’ preference for pumps over conventional multiple injection therapy has led 
to the development of new pumps of smaller size and more efficient performance 
[32]. Unfortunately, CSII therapy has a big drawback, namely increased risk of 
hypoglycemia [6, 31, 55, 57, 78]. The patients treated with CSII pump therapy 
become more vulnerable to severe hypoglycemic events, and some of the effects, 
such as confusion and unconsciousness, could result in the patient having several 
types of accidents. One of the reported adverse effect of the CSII treatment is weight 
gain [79] . As amount of diabetes patients is increasing all around the world, the need 
to solve the problem of calculating the proper insulin dosage and keeping track of 
blood glucose levels becomes increasingly urgent. Furthermore, the insulin infusion 
treatment is estimationof amount of insulin needed to control blood glucose level and 
it differs from one patient to another. Because of this, especially in T1D, insulin 
treatment must be as personalized as possible. The drawbacks highlighted so far 
include occasions when FLS does not match standard human performance and this 
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often relates to inadequate programming (it still requires an expert endocrinologist to 
set the rules for how an expert system should behave).  
2.5 Limitations 
Although there are plenty of other elements, only BMI and age were used in this 
study to personalize the treatment. These values were supposed to be called from a 
database, which contains other personal information about the patients. Instead of 
using database management, values were being recorded and retrieved from Excel 
files. In this study, glucose readings from a real diabetes patient were also recorded. 
Although the basal insulin rates are changing during the day according to the 
algorithm, this rate cannot be changed in the system manually. 
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3. MATERIALS AND METHODS 
3.1 Overview 
A general view of the system architecture can be seen in Figure 3.1. The database 
contains patient data, two fuzzy logic controllers determine coefficient factors, and a 
module called insulin on boardcalculates remaining amount of insulin in patient 
body. The main program (Figure 3.1) organizes the data flow; and is responsible for 
making prediction of insulin when patient’s blood glucose level is lower than normal.  
In this study, we did not use pump or blood glucose sensor while testing the system. 
However the results from the test phase were based on the blood glucose readings of 
a real type 1 diabetes patient. The response of this system and the proposed amount 
of insulin were also tested for different patient profiles listed in Table 3.1.  
The following sections give detailed information about the six sub-unit of the 
proposed system  and methods used in this study. 
3.2 Patient Database 
The first step of this study was to create datasets to record patient data such as 
patients’ identification number, name, age, and weight and body mass index (Table 
3.1).  As mentioned before the need of the insulin differs from one patient to another, 
because the way their body response the insulin is different. This patient database 
provides hourly calculated amount of insulin. The database consists of Excel files, 
which were used to store the patient information and amount of insulin that the 
system calculated and proposed for each patient. Moreover, we keep the fuzzy logic 
controllers linguistic rules and membership functions information in MATLAB 
format in this database. Therefore, Fuzzy Logic Algorithm 1 (FL1) and Fuzzy Logic 
Algorithm 2 (FL2) can form their fuzzy sets and apply their linguistic rules according 
to this information. 
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Figure 3.1 : Overview of system configuration 
Table 3.1 : Defined patients in patient database  
Patient No Weight(kg) BMI Age 
1 50 17 10 
2 110 18 18 
3 70 28 20 
4 100 25 25 
5 85 26 26 
6 60 17 35 
7 80 20 36 
8 120 28 40 
3.3 Fuzzy Logic Controller 
There are two different fuzzy logic control algorithms in this project (Figure 3.1). 
One of the fuzzy logic algorithms makes the treatment more personal according to 
the physical information of the patient coming from patient database, and the other 
one generates expected insulin amount and sends it to main controller unit. In this 
part we explain fuzzy logic algorithms of this system in more detail. 
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3.3.1 Fuzzy logic algorithm 1 
FL I has two input variables and one output variable (Figure 3.2). Input variables are 
age and body mass index of the patient and the output is a coefficient factor “k” 
which is the main variable to obtain the total daily amount of insulin (TDAI). In this 
prototype, an automatic tuning algorithm is generated by using another fuzzy logic 
algorithm for update the value of “k”.  Therefore “k” variable is changing according 
to the patient’s age and BMI. By using Equation (1) TDAI can be calculated. For the 
pump therapy only the 80% of this value is used [80].   
Body Mass Index
Age
Fuzzy logic
 Algorithm 1
Coefficent Factor «k»
 
Figure 3.2 : General structure of FL I 
 TDIA= Weight of the patient . k . (0.8)   (Unit) (3.1) 
As can be seen in Equation 1, TDIA is an output directly related with the k and 
Weight of the patient. Moreover, as k varies from patient to patient, TDAI also 
changes according to the output of the FL1. Basal rate of the insulin is calculated by 
using Equation (2). This formula gives as the average rate of basal insulin for one 
hour. Basal rate calculation is not dependent on the blood glucose level of the patient 
[34, 51, 80]. 
                       
  
(Unit/Hour) (3.2) 
Input variables’ membership functions and defined intervals can be seen in Figure 
3.3 and Figure 3.4. All the information obtained from a specialistin endocrinology 
and metabolism. Figure 3.4 shows that the output of the FL1. Therefore “k” varies 
between 0.1 and 0.7. Also the coefficient factor “k” has another crucial role in 
proposed system, changing the output membership function of FL II (Figure 3.6). 
Therefore when a patient’s BMI or age is getting higher, the expected insulin is 
increased. However, between the ages 11 and 20 basal requirement is relatively 
higher than the other age groups [40].   
 40 
 
Figure 3.3 : Input variable membership function plots representing BMI in  FL I 
 
Figure 3.4 : Input variable membership function plots representing Age in  FL I 
 
Figure 3.5 : Output variable membership function plots representing Coefficient factor “k” 
according to  FL I 
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3.3.2 Fuzzy logic algorithm 2 
The FL II compares arbitrary taken blood glucose readings. Our system has three 
inputs and one output (Figure 3.6). This control algorithm compares the inputs and 
generates anoutput according to the linguistic rules coming from the patient database.  
 
Figure 3.6 : General structure of FL II  
 
Figure 3.7 : Input variable membership function plots representing BGL in  FLII 
Our inputs are blood glucose values called BG1, BG2 and BG3 that represent the 
arbitrary continuous readings from BGL sensor. BG3 represents the value of blood 
glucose at the current moment. According to this information, BG2 is the value of 
blood glucose of 1 hour earlier and BG1 is that of 2 hours earlier. They have 
identically the same membership functions and intervals, as stated in Figure 3.7. 
There are five membership functions in FLII input sets. Names of these functions 
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represent different levels of blood glucose. By comparing the differences between 
the inputs, the output is calculated according to the rules suggested by the specialist  
By using FL II (Figure 3.1) the system can adapt itself to different situations 
comparing readings coming from sensor. The output set is formed by defining six 
different membership functions (Figure 3.8). These functions represent the expected 
amount of insulin. 
 
Figure 3.8 : Output variable membership function plots representing Suggested 
insulin according to FL II 
To characterize the logical connection between inputs and output, 95 linguistic “if-
then” rules were defined in our FL II control algorithm. Some of the linguistic rules 
are given below. All of the linguistic rules were listed in Appendix 1. 
<Rule 1: if BG1 is normal and BG2 is normal and BG3 is normal then insulin is low> 
<Rule 5: if BG1 is normal BG2 is normal and BG3 is danger  then insulin is high> 
<Rule 12: if BG1 is normal BG2 is very-high  and BG3 is high  then insulin is medium> 
3.4 Main Control Unit 
Main control unit is responsible for multiple actions. One of them is controlling the 
data flow coming from fuzzy control unites and insulin on board detector (Figure 
3.1). Main controller combines insulin dosages and generates a calculated dosage 
from expected insulin and pre-calculated insulin. This calculated insulin is sent to the 
electro mechanic device (pump). Another important factor that is controlled by 
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insulin is the basal insulin rates. In addition, main program in the system is 
responsible for keeping track of time and calculation of basal insulin amount 
according to the TDAI. This calculation is independent from the blood glucose level 
of the patient. Basal insulin requirements vary during the day and night. Especially in 
the nighttime and early morning, the requirement of the insulin increases. Moreover, 
with the factors of age and sex, basal insulin requirement varies too [40].  In this 
study basal rate is changed automatically by main controller. There is not a patient 
interface for changing the basal rate. In Figure 3.9, calculated basal rate profile with 
respect to the time, can be seen clearly. Blue arrows represent the time that the basal 
rate of insulin is increased by the program automatically. 
 
Figure 3.9 : Basal infusion rate profile 
Main controller also checks the BGL of the patient. If the BGL is too low, main 
controller shuts the system off until BGL returns back to the normal interval. Even if 
the system is off, calculated basal insulin dosages will still be injected to the T1D 
patient to keep his metabolism alive. 
3.5 Insulin on Board Module 
Insulin pumps use fast acting insulin that is, given insulin is effective 2 to 5 hours in 
patient body. Only approximately 20% of the given insulin can enter the blood 
stream. So the other 80% remains in the injection site [81] (Table 3.2).  
If you rapidly intake carbohydrate, insulin doses can begin to overlap. Hence blood 
glucose level of the patient can drop dangerously. To avoid hypoglycemic events, the  
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Table 3.2 : Residual insulin amount [81] 
Dose Given  
(Unit) 
Units Left to Work After 
1 Hour 2 Hour 3 Hour 4 Hour 5 Hour 
1 0,8 u 0,6 u 0,4 u 0,2 u 0 
2 1,6 u 1,2 u 0,8 u 0,4 u 0 
3 2,4 u 1,8 u 1,2 u 0,6 u 0 
4 3,2 u 2,4 u 1,6u 0,8 u 0 
5 4 u 3 u 2 u 1 u 0 
 
expected insulin amount need to be corrected by insulin on board (see Figure 2.1). 
This module keeps track of insulin that still remains at the injection site. Thus the 
system “knows” how many units of given insulin still remain. 
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4. RESULTS 
This chapter presents the performance of the control system designed in this project. 
The prototype system in this study is coded in MATLAB programming language. 
We used MATLAB fuzzy logic toolbox to create Mamdani type fuzzy membership 
functions and graphics. The main reason to use fuzzy control algorithms is to 
develope an “adaptive controller” mechanism that can mimic a simplified form 
ofhuman fuzzy thinking [53]. 
To evaluate our prototype system’s performance under different conditions, several 
scenarios have been simulated. Particularly, the designed system was tested for its 
abilities to generate proper coefficient factor “k” for different patients, avoiding 
insulin on board effect and handling meal disturbances.  
4.1 System Test with Test Patients 
Out model was tested against patient profiles of different physical condition and 
different levels of insulin. After these simulations, we used a real Type 1 Diabetes 
patient who had her treatment using MDI method. Our model’s efficiency was tested 
by comparing patients’ daily dosages. In order to study the effectiveness of the 
tuning algorithm, purposed insulin dosages wereinjected to a volunteer T1D patient. 
Results were obtained as blood glucose levels. Calculated results were recorded and 
represented in this chapter. 
The blood glucose data recorded from the real T1D patient were used to test the 
system. Our test patient was 74 years old female. Herweight was 79,8 kg and height 
1,66 m. Same data were also tested for different body mass indices and ages. 
Suggested amounts of insulin were presented as a function of time. The test results 
and the blood glucose levels were presented as daily bases. 
Figure 4.1 shows one day blood glucose levels, whichwere not constant and change 
during the day for the real T1D patient. When it becomes higher, then the patient 
needs insulin to reduce it, until a normal interval, which is between 70-120 mg/dl 
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Figure 4.1 : Blood glucose levels of the patient for Monday 
is reached [50, 80]. The test patient was treated by multiple daily injection insulin 
therapy to keep his blood glucose levels in between normal levels. This patient was 
injected insulin five times a day. As shown in the Table 3.1, 3three of these 
injections were bolus doses and the others 4 basal doses. Her total daily amount of 
insulin was 56 units.  
Table 4.1 : Test patient’s daily insulin injections 
Hour Bolus Doze (Unit) Basal Doze (Unit) 
08:00-08:20 12 U 12 U 
12:30-13:00 8 U 0 U 
18:30-19:45 12 U 12 U 
Total 32 U 24 U 
 
The system was designed to readreal blood glucose data as input data (Figure 4.1). 
Hence there are 144 blood glucose values and 144 calculated expected insulin doses.. 
The program starts Monday at 01:00 am, and finishes Saturday at 00:00 pm. The 
start and stop times can be changed in the main program. To validate the outputs of 
system, we used the data obtained from a real T1D patient treatment. First, we 
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collected and recorded the data in the database as if they were coming from a sensor 
on an hourly basis. This sensor was supposed to be placed on the abdominal region 
of the patient and it supposedly measured the blood glucose of the tissue fluid. 
Patient was supposedly tested for blood sugar levels 4 times a day. After 6 days a 
special program combined blood sugar levels and tissue fluid sugar levels and gave 
us the glucose profile of the patient. These values were used as test data for blood 
sugar level. 
Different patient profiles were defined in the patient database (Table 3.1). The main 
program starts to work with entering a patient number. For instance, if we write 5 as 
a patient number, as can be seen in Table 3.1, the body mass index and age for this 
patient will be loaded to the system. Then first fuzzy control algorithm will give us 
the coefficient factor “k” for the patient in concern. The different “k” outputs are 
listed in Table 4.2. The resulted “k” value depended on the patient’s physical 
properties.  
This system was tested on 8 different patient profiles using same blood glucose 
readings. For example; Figure 4.2 shows the suggested insulin for test patient for first 
24 hours. It is obvious that when the blood glucose level sharply rises, the calculated 
insulin rises as well. As indicated in Figure 4.2, at 20:00 blood glucose level reached 
its maximum value (182 mg/dl) for Monday. Also the system suggested the 
maximum amount of insulin which is 4,65 units.  Moreover, at 21:00 the blood 
glucose level was normalized and calculated insulin was reduced. Additionally, in 
Figure 4.3, you can see the blood glucose readings for Thursday and the system’s 
output according to the information of the test patient.  
Table 4.2 : Calculated coefficient factor and average basal rates for defined patients 
in the database  
Patient Number CoefficientFactor Average Basal Rate 
1 0.3477 0.2897 
2 0.3550 0.6508 
3 0.2534 0.2956 
4 0.6533 1.0887 
5 0.6620 0.9379 
6 0.6653 0.6353 
7 0.6684 0.8912 
8 0.6738 1.347 
Figure 4.3, Figure 4.4 and Figure 4.5 indicate that our system is adaptive, unlike the 
multiple daily injection therapy (Table 4.1), the suggested amount of insulin varies 
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according to the changes in blood glucose level. In Figure 4.2, the test results of 2 
different patients with different profiles are compared. Especially the hours between 
04:00 and 19:00 the proposed insulin amounts were completely different. It is 
obvious that for different profiles, system output changed. This feature gives an 
opportunity to apply personal insulin treatment for every patient. 
In, Figure 4.3, if you sum all the injections amounts, you get the total daily insulin 
therapy for the test patient. Total insulin amount for Monday is 42,82 units. As can 
be seen in Table 4.1, patient needed 52 units of insulin for multiple daily injection 
therapy. In Table 4.3, you can find the proposed insulin amounts according to the 
days. Daily Insulin MDI is representing the total insulin amount that the patient 
needs to inject herself everyday, no matter the how the BGL is. Daily Insulin 
Proposed represents the total insulin amount which is proposed by our system. 
Percentage represents how much percent  Daily Insulin MDI is used by the system. 
 
Figure 4.2 : Comparison of results of Patient 3 and Patient 8 
In Table 4.3, you can see the percentages between TDAI total MDI units and 
proposed units. Generally, it is accepted that 80% is enough when the patient start to 
use a pump. Yet, as you see on Tuesday (Figure 4.4), Friday (Figure 4.6), and 
Saturday (Figure 4.7) percentages were above the expectedvaluebecause of the high 
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Table 4.3 : Comparison between total MDI units and proposed insulin 
Day 
Daily Insulin 
MDI 
Proposed Insulin Percentage 
Monday 54 U 42,82 U % 79 
Tuesday 54 U 50,8 U % 99 
Wednesday 54 U 40,80 U % 75,55 
Thursday 54 U 42,6 U % 78,88 
Friday 54 U 78,09 U % 144 
Saturday 54 U 71,46 U % 132 
 
blood glucose levels of the patient. It can be clearly seen in the mentioned days the 
BGL profile of the patient was very high and with the information in the table we can 
say the insulin need of the patient was higher than the other days. Therefore, our 
system exceeds the TDAI and proposes a new insulin profile which is created 
according to the patient’s BGL profile. Also, this information leads us into another 
inference; TDAI cannot be adjusted by user without asking an expert’s help when 
you use MDI treatment. However, our system kept track of your BGL and insulin 
level and tried to adjust itself to the changing BGL conditions. 
 
Figure 4.3 : Suggested insulin profile for the test patient on Monday 
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Figure 4.4 : Suggested insulin profile for the test patient on Tuesday  
 
 
Figure 4.5 : Test patient’s calculated insulin profile for Wednesday  
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Figure 4.6 : Suggested insulin profile for the test patient on Thursday 
 
Figure 4.7 : Suggested insulin profile for the test patient on Friday 
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Figure 4.8 : Suggested insulin profile for the test patient on Saturday 
As indicated in Figure 4.5, at 01:00 blood glucose level was 39,6 mg/dl. As a 
response, system calculated 0,89 units of insulin. If blood glucose level is lower than 
60mg/dl, main algorithm stops the system until the blood glucose levels reach a 
sufficient value or higher (70mg/dl-120mg/dl) [8, 29]. If we continue to give more 
insulin when patient’s blood glucose levels are very low, patient will suffer from 
hypoglycemia [80]. Even though the system is switched off, main programs continue 
to give the basal insulin.  
Also as shown in the Figure 4.6, at 15:00, the blood glucose levels were not very 
different from the previous readings; however the calculated insulin was very low. 
The reason for this fluctuation is the correction made by the insulin on board detector 
which is an important module in the program. At 14:00 high amount of insulin was  
injected to the patient’s body. Thus in injection site, there will be insulin (Table 4.1). 
To prevent overlapping of the insulin doses at 15:00, less insulin was injected to let 
the body use the previously injected insulin.  
Figure 4.9 shows the differences between the patient’s blood insulin amount and 
purposed insulin levels. As you know, T1D patients who use MDI therapy injects 
themselves insulin several times during the day (Table 4.1) to keep the BGL in 
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optimum interval. By comparing the two values we clearly see differences between 
CSII and MDI therapy. In contrast, especially at 01:00 and time interval between  
 
Figure 4.9 : Comparison of patient’s blood insulin amount and purposed insulin 
amount for Monday 
18:00 and 21:00, need of insulin was increasing according to the high BGL of the 
patient. Our results matched with the doctor approved MDI therapy. When the 
insulin profile of the patient was higher and our system proposed a high level of 
insulin to reduce BGL as MDI therapy does. Hence this figure shows that the results 
matched  when the need of insulin was increasing due to the glucose ingestion. In 
contrast, between the 08:00 and 14:00, there was only one big peak but our system 
purposed two small peaks. Reason for this is the insulin on board module. After 
giving a high level of insulin, insulin on board module keeps track of the given 
insulin and adjust the other insulin dosages. 
The main program and fuzzy logic control algorithms were tested with a sample of 
real blood glucose data taken from a T1D patient who was treated by multiple daily 
injections for 6 days. Patient profiles, blood glucose readings and suggested amount 
of insulin are stored in Excel files representing the patient database. Every profile is 
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tested with the same blood glucose readings. Hence the system outputs cannot affect 
the blood glucose values. 
4.2 System test with a real patient 
In our last test, suggested insulin dosages applied to a real T1D patient. Patient was 
24 years old male. His weight was 85 kg and his height 1.87 m. Therefore his BMI 
was 24, 35 kg/m
2. 
All his physical information was loaded to the system and 
coefficient factor value was calculated. Then our simulation started at 07:00 am (1
st
 
hour of the test) (Figure 3.6), before the breakfast time. Yet, as we mentioned in 
chapter 2, to calculate the needed insulin system has to compare 3 results. Thus, our 
patient started to keep track of the blood glucose levels from 5:00 am. At 7:00 am 
system had the 3 measured blood glucose levels and produced the first insulin dose. 
After an hour, another blood glucose level test wasperformed by our patient and 
another output was generated. The determined insulin amounts were directly applied 
to our patient’s belly using an insulin pen. For this test, only fast acting insulin was 
used.  
 
Figure 4.10 : Real patient’s recorded blood glucose levels and suggested insulin 
dosages 
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Figure 4.10 represents data for 20 hours, and there were 18 insulin dosages that were 
suggested by the system as an output.  As shown in the figure, in 3rd hour of the test, 
patien started to digest his breakfast and his blood glucose levels became higher. As 
a response to this, the system generated higher amounts of insulin to reduce the BGL. 
At the 11
th
 hour of the test BGL was still increasing because of the dinner. An 
interesting fact is that at the 14
th
 hour BGL of the patient was increased more than 
the 11
th
 hour but then 14
th
 purposed insulin amount was less the 11
th
 dosage. The 
main reason for this is the insulin on board detector which prevents unwanted 
hypoglycemic events. 
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5. CONCLUSIONS AND FUTURE WORKS 
In this study we developed a prototype system based on Mamdani type fuzzy logic 
controllers for T1D patients to propose expected amount of insulin. The system 
suggests insulin dosage according to the age, body mass index and weight of the 
patients and adapts the output according to the general profile of the glucose 
readings. The program keeps the track of the injected amount of insulin to prevent 
hypoglycemic events. In addition patient data, the calculated amount of insulin and 
glucose readings can be stored in the database for data management purposes.  
The developed prototype was tested by using data from a real T1D patient. We used 
a test environment without a real sensor and a pump, but different kinds of patient 
profiles were tested.  Results showed that system was adaptable and for every patient 
data, it calculated expected amount of insulin to keep the blood glucose level 
optimal. Calculating the proper insulin level is important to control blood glucose 
levels but also measuring the levels is another important part of the process.  
Features in this prototype can also be used for educational purposes, but a new study 
with a real sensor and pump is required for validation. As Raine implies “blood 
glucose meter coding errors may result in significant insulin dosing errors. To avoid 
errors, patients should be instructed to keep track of their meters performance 
manually” [82]. Therefore, making measurementsisessential for close loop systems 
to keep the blood glucose levels in desired intervals. To achieve this the proper blood 
glucose sensor must be integral part of the system to keep track of the glucose levels 
[30]. 
Another important feature that we have to use in the future is voice control for 
pumps. Lorraine [83] highlighted the fact that industry should design pumps with 
features that can be safely and easily accessed by people with severe vision loss. 
Serious health consequences can result from improper use of insulin pumps by 
visually impaired people with T1D. 
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Hence insulin pump therapy has many advantages; they are widely used among the 
young T1D patients. Insulin pump manufacturers are expected to develop smarter 
pumps which can handle more functionality in the future. Control loop for CSII 
therapy can be closed to propose accurate insulin dosages for diabetes patients 
through newly developed pump features. Sometime soon, with the developments in 
the continuous glucose sensor, implantable insulin pumps will be manufactured. This 
development will revolutionize diabetes treatment.  
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APPENDIX A.1 
 
<Rule 1: if BG1 is low and BG2 is low and BG3 is low then insulin is low > 
<Rule 2: if BG1 is low and BG2 is low and BG3 is normal then insulin is low > 
<Rule 3: if BG1 is low and BG2 is low and BG3 is high then insulin is medium > 
<Rule 4: if BG1 is low and BG2 is low and BG3 is very-high then insulin is high > 
<Rule 5: if BG1 is low and BG2 is low and BG3 is danger then insulin is extreme-
high > 
<Rule 6: if BG1 is low and BG2 is normal and BG3 is low then insulin is low > 
<Rule 7: if BG1 is low and BG2 is normal and BG3 is normal then insulin is normal 
> 
<Rule 8: if BG1 is low and BG2 is normal and BG3 is high then insulin is medium > 
<Rule 9: if BG1 is low and BG2 is normal and BG3 is very-high then insulin is 
very-high > 
<Rule 10: if BG1 is low and BG2 is normal and BG3 is danger then insulin is 
extreme-high > 
<Rule 11: if BG1 is low and BG2 is high and BG3 is low then insulin is low > 
<Rule 12: if BG1 is low and BG2 is high and BG3 is normal then insulin is normal > 
<Rule 13: if BG1 is low and BG2 is high and BG3 is high then insulin is high > 
<Rule 14: if BG1 is low and BG2 is high and BG3 is very-high then insulin is very-
high > 
<Rule 15: if BG1 is low and BG2 is high and BG3 is danger then insulin is extreme-
high > 
<Rule 16: if BG1 is low and BG2 is very-high and BG3 is normal then insulin is 
normal > 
<Rule 17: if BG1 is low and BG2 is very-high and BG3 is high then insulin is 
medium > 
<Rule 18: if BG1 is low and BG2 is very-high and BG3 is very-high then insulin is 
very-high > 
<Rule 19: if BG1 is low and BG2 is very-high and BG3 is danger then insulin is > 
<Rule 20: if BG1 is low and BG2 is danger and BG3 is high then insulin is high > 
<Rule 21: if BG1 is and BG2 is danger and BG3 is very-high then insulin is very-
high > 
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<Rule 22: if BG1 is and BG2 is danger and BG3 is danger then insulin is extreme-
high > 
<Rule 23: if BG1 is normal and BG2 is low and BG3 is low then insulin is low > 
<Rule 24: if BG1 is normal and BG2 is low and BG3 is normal then insulin is 
normal > 
<Rule 25: if BG1 is normal and BG2 is low and BG3 is high then insulin is medium 
> 
<Rule 26: if BG1 is normal and BG2 is low and BG3 is very-high then insulin is 
high > 
<Rule 27: if BG1 is normal and BG2 is low and BG3 is danger then insulin is 
extreme-high > 
<Rule 28: if BG1 is normal and BG2 is normal and BG3 is low then insulin is low > 
<Rule 29: if BG1 is normal and BG2 is normal and BG3 is normal then insulin is 
normal > 
<Rule 30: if BG1 is normal and BG2 is normal and BG3 is high then insulin is 
medium > 
<Rule 31: if BG1 is normal and BG2 is normal and BG3 is very-high then insulin is 
very-high > 
<Rule 32: if BG1 is normal and BG2 is normal and BG3 is danger then insulin is 
extreme-high > 
<Rule 33: if BG1 is normal and BG2 is high and BG3 is then lowinsulin is low > 
<Rule 34: if BG1 is normal and BG2 is high and BG3 is normal then insulin is 
normal > 
<Rule 35: if BG1 is normal and BG2 is high and BG3 is high then insulin is high > 
<Rule 36: if BG1 is normal and BG2 is high and BG3 is very-high then insulin is 
very-high > 
<Rule 37: if BG1 is normal and BG2 is high and BG3 is then insulin is extreme-high 
> 
<Rule 38: if BG1 is normal and BG2 is very-high and BG3 is then normal insulin is 
> 
<Rule 39: if BG1 is normal and BG2 is very-high and BG3 is high then insulin is 
medium > 
<Rule 40: if BG1 is normal and BG2 is very-high and BG3 is very-high then insulin 
is very-high > 
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<Rule 41: if BG1 is normal and BG2 is very-high and BG3 is danger then insulin is 
> 
<Rule 42: if BG1 is normal and BG2 is danger and BG3 is then high insulin is 
medium > 
<Rule 43: if BG1 is normal and BG2 is danger and BG3 is very-high then insulin is 
very-high > 
<Rule 44: if BG1 is normal and BG2 is danger and BG3 is danger then insulin is 
extreme-high > 
<Rule 45: if BG1 is high and BG2 is low and BG3 is low then insulin is low > 
<Rule 46: if BG1 is high and BG2 is low and BG3 is normal then insulin is normal > 
<Rule 47: if BG1 is high and BG2 is low and BG3 is high then insulin is medium > 
<Rule 48: if BG1 is high and BG2 is low and BG3 is very-high then insulin is high > 
<Rule 49: if BG1 is high and BG2 is low and BG3 is danger then insulin is extreme-
high > 
<Rule 50: if BG1 is high and BG2 is normal and BG3 is low then insulin is low > 
<Rule 51: if BG1 is high and BG2 is normal and BG3 is normal then insulin is 
normal > 
<Rule 52: if BG1 is high and BG2 is normal and BG3 is high then insulin is medium 
> 
<Rule 53: if BG1 is high and BG2 is normal and BG3 is very-high then insulin is 
very-high > 
<Rule 54: if BG1 is high and BG2 is normal and BG3 is danger then insulin is 
extreme-high > 
<Rule 55: if BG1 is high and BG2 is high and BG3 is low then insulin is low > 
<Rule 56: if BG1 is high and BG2 is high and BG3 is normal then insulin is normal 
> 
<Rule 57: if BG1 is high and BG2 is high and BG3 is high then insulin is high > 
<Rule 58: if BG1 is high and BG2 is high and BG3 is very-high then insulin is very-
high > 
<Rule 59: if BG1 is high and BG2 is high and BG3 is danger then insulin is 
extreme-high > 
<Rule 60: if BG1 is high and BG2 is and BG3 is normal then insulin is low > 
<Rule 61: if BG1 is high and BG2 is very-high and BG3 is high then insulin is 
medium > 
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<Rule 62: if BG1 is high and BG2 is very-high and BG3 is very-high then insulin is 
very-high > 
<Rule 63: if BG1 is high and BG2 is very-high and BG3 is danger then insulin is 
extreme-high > 
<Rule 64: if BG1 is high and BG2 is danger and BG3 is high then insulin is medium 
> 
<Rule 65: if BG1 is high and BG2 is danger and BG3 is very-high then insulin is 
very-high > 
<Rule 66: if BG1 is high and BG2 is danger and BG3 is then insulin is extreme-high 
> 
<Rule 67: if BG1 is very-high and BG2 is normal and BG3 is low then insulin is low 
> 
<Rule 68: if BG1 is very-high and BG2 is normal and BG3 is normal then insulin is 
normal > 
<Rule 69: if BG1 is very-high and BG2 is normal and BG3 is high then insulin is 
medium > 
<Rule 70: if BG1 is very-high and BG2 is normal and BG3 is very-high then insulin 
is very-high > 
<Rule 71: if BG1 is very-high and BG2 is and BG3 is then insulin is danger > 
<Rule 72: if BG1 is very-high and BG2 is high and BG3 is low then insulin is low > 
<Rule 73: if BG1 is very-high and BG2 is high and BG3 is normal then insulin is 
normal > 
<Rule 74: if BG1 is very-high and BG2 is high and BG3 is high then insulin is 
medium > 
<Rule 75: if BG1 is very-high and BG2 is high and BG3 is very-high then insulin is 
very-high > 
<Rule 76: if BG1 is very-high and BG2 is high and BG3 is danger then insulin is 
extreme-high > 
<Rule 77: if BG1 is very-high and BG2 is very-high and BG3 is then insulin is low 
> 
<Rule 78: if BG1 is very-high and BG2 very-high is and BG3 is then high insulin is 
high > 
<Rule 79: if BG1 is very-high and BG2 very-high is and BG3 is very-high then 
insulin is very-high > 
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<Rule 80: if BG1 is very-high and BG2 is very-high and BG3 is danger then insulin 
is extreme-high > 
<Rule 81: if BG1 is very-high and BG2 is danger and BG3 is high then insulin is 
medium > 
<Rule 82: if BG1 is very-high and BG2 is danger and BG3 is very-high then insulin 
is very-high > 
<Rule 83: if BG1 is very-high and BG2 is danger and BG3 is then insulin is 
extreme-high > 
<Rule 84: if BG1 is danger and BG2 is high and BG3 is low then insulin is low > 
<Rule 85: if BG1 is danger and BG2 is high and BG3 is normal then insulin is 
normal > 
<Rule 86: if BG1 is danger and BG2 is high and BG3 is high then insulin is medium 
> 
<Rule 87: if BG1 is danger and BG2 is high and BG3 is very-high then insulin is 
very-high > 
<Rule 88: if BG1 is danger and BG2 is high and BG3 is danger then insulin is 
extreme-high > 
<Rule 89: if BG1 is danger and BG2 is very-high and BG3 is normal then insulin is 
low > 
<Rule 90: if BG1 is danger and BG2 is very-high and BG3 is high then insulin is 
medium > 
<Rule 91: if BG1 is danger and BG2 is very-high and BG3 is very-high then insulin 
is high > 
<Rule 92: if BG1 is danger and BG2 is very-high and BG3 is danger then insulin is 
extreme-high > 
<Rule 93: if BG1 is danger and BG2 is danger and BG3 is high then insulin is 
medium > 
<Rule 94: if BG1 is danger and BG2 is danger and BG3 is very-high then insulin is 
very-high > 
<Rule 95: if BG1 is danger and BG2 is danger and BG3 is danger then insulin is 
extreme-high > 
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